Late-Breaking Phase 2 MSS mCRC with high plasma TM
Post# of 158771
(Total Views: 625)
Posted On: 11/09/2025 11:52:31 AM
Late-Breaking Phase 2 MSS mCRC with high plasma TMB data for vilastobart + atezolizumab at SITC.
40% ORR
https://ir.xiliotx.com/news-releases/news-rel...ase-2-data
"Based on the differentiated profile demonstrated by vilastobart as a combination therapy, Xilio is actively seeking a partner to continue to develop vilastobart in combination with PD-(L)1 and/or PD1-VEGF in MSS CRC and other tumor types."
Can't wait for us to start releasing results...
40% ORR
https://ir.xiliotx.com/news-releases/news-rel...ase-2-data
"Based on the differentiated profile demonstrated by vilastobart as a combination therapy, Xilio is actively seeking a partner to continue to develop vilastobart in combination with PD-(L)1 and/or PD1-VEGF in MSS CRC and other tumor types."
Can't wait for us to start releasing results...
(3)
(0)